Skin Reactions
Patients taking Exifine are at an increased risk. These patients may experience serious skin reaction such as life-threatening allergic reactions and drug-induced life-threatening allergic reactions. Exifine should be discontinued on the occurrence of progressive skin rash.
Inflammation of the Connective Tissues (Lupus Erythematous)
Patients taking Exifine are at an increased risk. These patients may experience
lupus erythematosus. Exifine should be discontinued on the occurrence of signs and symptoms of lupus erythematosus. Precaution should be taken in patients with
psoriasis or lupus erythematosus.
Medicinal Products Metabolized by CYP2D6
Patients taking Exifine with medicinal products metabolized by CYP2D6 are at an increased risk. Dose adjustment should be considered in such patients.
Functioning Of the Kidney
Patients with an abnormality in the functioning of the kidney are at an increased risk. Exifine should not be in such patients.
Harmful Effects on Liver
Patients using Exifine, with and without liver disease are at an increased risk. These patients may experience
nausea,
fatigue, stomach
pain,
jaundice, dark urine, eating disorder (anorexia), pale
stools, harmful effects of the liver, or liver failure which may lead to liver transplant or fatality. If this happens, stop taking Exifine and contact your doctor as soon as possible. In this case, the blood test should be performed for liver problems before using Exifine.
Taste Disturbance
Patients taking Exifine are at an increased risk. These patients may experience taste disturbance such as taste loss, which may lead to weight loss, decreased food intake, and
depressive symptoms. Exifine should be discontinued on the occurrence of taste disturbance. These symptoms may resolve after discontinuation of Exifine therapy, but these symptoms may be prolonged or permanent.
Smell Disturbance
Patients taking Exifine are at an increased risk. These patients may experience smell disturbance such as loss of smell. Exifine should be discontinued on the occurrence of smell disturbance. These symptoms may resolve after discontinuation of Exifine therapy but may be prolonged or permanent.
Depressive Symptoms
Patients taking Exifine are at an increased risk. These patients may experience
depressive symptoms. Patients should be informed to report the doctor immediately on the occurrence of depressive symptoms.
Blood-Related Effects
Patients taking Exifine are at an increased risk. These patients may experience low levels of blood cells such as neutrophils, granulocytes, thrombocytes, white blood cells,
platelets or red blood cells,
fever, and sore throat. Complete blood count test and blood-related effects should be examined on the occurrence of symptoms of secondary infection and in patients with immunodeficiency using Exifine for more than six weeks. Exifine should be discontinued on the occurrence of severe low levels of blood cells. Also, dose adjustment and supportive therapy should be considered in such cases.